Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWOG phase III trial of gemtuzumab ozogamicin added to induction and post-consolidation therapy in younger adults with newly diagnosed de novo acute myeloid leukemia
2006-002743-89Phase 3Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 2007
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (4 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Disease-free survival. Started Feb 2007; status: terminated.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-002743-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002743-89.